New Dopamine D1 Agonists as PET Imaging Agents
作为 PET 成像剂的新型多巴胺 D1 激动剂
基本信息
- 批准号:7206829
- 负责人:
- 金额:$ 15.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAvidityBindingBinding SitesBrainCognitionCyclotronsDevelopmentDiseaseDopamineDopamine AgonistsDopamine AntagonistsDopamine D1 ReceptorDopamine D2 ReceptorDopamine ReceptorDrug LabelingEvaluationFamilyGoalsHealthImageIonsIsotopesLabelLigand BindingMacaca mulattaMeasuresMethodsMovementNeurosecretory SystemsPharmacologic SubstancePositronPositron-Emission TomographyProductionProtonsRewardsRoleSamplingSiteWorkbasefunctional statusneurochemistryneuropsychiatrynovelreceptor binding
项目摘要
DESCRIPTION (provided by applicant): Dopamine is a neurochemical involved in many critical brain functions including movement, cognition, neuroendocrine and reward. There are two families of dopamine receptors, dopamine D1 subtypes and dopamine D2 subtypes. Positron emission tomography (PET) imaging has been very useful in understanding the roles of dopamine receptors in health and disease. While PET imaging agents targeted to dopamine D2 receptors are well developed, the same can not be said for dopamine D1 PET imaging agents. Both dopamine receptor subtypes exist in two binding states- high affinity states and low affinity states. Dopamine has nanomolar affinity for high affinity states and micromolar affinity for low affinity states. Because the high Affinity state is the physiologically functional state, dopamine agonists are preferred as PET imaging agents since they can discriminate between high and low affinity states. In contrast dopamine antagonists bind both high and low affinity states with equal avidity. The understanding of dopamine D2 receptors is more mature than the understanding of dopamine D1 receptors due in part to the paucity of dopamine D1 PET imaging agents. The goal of this proposal is to develop high affinity and highly selective dopamine D1 agonists as PET imaging agents based on a group of 6-chloro-phenylbenzazepines with promising affinities and selectivities. We plan to label these agonists with a novel PET isotope, Cl-34m (tVz = 32 min, 53%.{3+). The specific aims of this project are (1) develop routine Cl-34m production methods using a small 11 Mev proton cyclotron, (2) prepare cold authentic samples of 6-chloro-phenylbenzazepines and their derivatives suitable as precursors for positron labeling, (3) develop routine radiosynthesis of high affinity Cl-34m dopamine D1 agonists and (4) perform preliminary microPET imaging to evaluate and validate Cl-34m-labeled dopamine D1 agonists as PET imaging agents in rhesus macaques. There is currently no reliable Cl-34m production method. Successful development of Cl-34m production methods will allow the evaluation of many chlorinated Pharmaceuticals. In addition, new dopamine D1 agonists labeled with Cl-34m will extend the utility of PET rnaging toward better understanding of the role of dopamine D1 receptors in neuropsychiatric disorders. PET imaging with dopamine D1 agonists will facilitate the understanding and treatment of dopamine D1- related neuropsychiatric disorders.
描述(由申请人提供):多巴胺是一种神经化学物质,参与许多关键的大脑功能,包括运动、认知、神经内分泌和奖励。多巴胺受体有两个家族,多巴胺D1亚型和多巴胺D2亚型。正电子发射断层扫描(PET)成像在了解多巴胺受体在健康和疾病中的作用方面非常有用。虽然靶向多巴胺D2受体的PET显像剂已经开发得很好,但多巴胺D1 PET显像剂的情况并非如此。两种多巴胺受体亚型都以两种结合状态存在-高亲和力状态和低亲和力状态。多巴胺对高亲和力状态具有纳摩尔亲和力,对低亲和力状态具有微摩尔亲和力。因为高亲和力状态是生理功能状态,所以多巴胺激动剂优选作为PET成像剂,因为它们可以区分高亲和力状态和低亲和力状态。相反,多巴胺拮抗剂以相等的亲合力结合高亲和力和低亲和力状态。对多巴胺D2受体的理解比对多巴胺D1受体的理解更成熟,部分原因是多巴胺D1 PET显像剂的缺乏。该提案的目标是开发高亲和力和高选择性的多巴胺D1激动剂作为PET显像剂的基础上,一组6-氯-苯基苯并氮杂卓具有良好的亲和力和选择性。我们计划用新型PET同位素Cl-34 m(tVz = 32 min,53%)标记这些激动剂。{3+)。该项目的具体目标是:(1)使用小型11 Mev质子回旋加速器开发常规Cl-34 m生产方法,(2)制备适合作为正电子标记前体的6-氯苯基苯并氮杂卓及其衍生物的冷真实样品,(3)开发高亲和力Cl-34 m多巴胺D1激动剂的常规放射合成和(4)进行初步的microPET成像以评估和验证Cl-34 m多巴胺D1激动剂的放射合成。34 m标记的多巴胺D1激动剂作为恒河猴PET显像剂。目前还没有可靠的Cl-34 m生产方法。Cl-34 m生产方法的成功开发将允许对许多氯化药物进行评估。此外,用Cl-34 m标记的新的多巴胺D1激动剂将扩展PET成像的效用,以更好地理解多巴胺D1受体在神经精神疾病中的作用。多巴胺D1激动剂的PET成像将有助于了解和治疗多巴胺D1相关的神经精神疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Onofre DeJesus其他文献
Onofre DeJesus的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Onofre DeJesus', 18)}}的其他基金
MATERNAL-FETAL TRANSPORT OF NEUROTOXINS USING PET IMAGING
使用 PET 成像进行神经毒素的母体-胎儿转运
- 批准号:
8358213 - 财政年份:2011
- 资助金额:
$ 15.88万 - 项目类别:
MATERNAL-FETAL TRANSPORT OF NEUROTOXINS USING PET IMAGING
使用 PET 成像进行神经毒素的母体-胎儿转运
- 批准号:
8173105 - 财政年份:2010
- 资助金额:
$ 15.88万 - 项目类别:
MATERNAL-FETAL TRANSPORT OF NEUROTOXINS USING PET IMAGING
使用 PET 成像进行神经毒素的母体-胎儿转运
- 批准号:
7958784 - 财政年份:2009
- 资助金额:
$ 15.88万 - 项目类别:
MATERNAL-FETAL TRANSPORT OF NEUROTOXINS USING PET IMAGING
使用 PET 成像进行神经毒素的母体-胎儿转运
- 批准号:
7716461 - 财政年份:2008
- 资助金额:
$ 15.88万 - 项目类别:
New Dopamine D1 Agonists as PET Imaging Agents
作为 PET 成像剂的新型多巴胺 D1 激动剂
- 批准号:
7391136 - 财政年份:2007
- 资助金额:
$ 15.88万 - 项目类别:
ENZYME TARGETED IMAGING AGENTS FOR NEUROPSYCHIATRY
用于神经精神病学的酶靶向成像剂
- 批准号:
6309171 - 财政年份:2000
- 资助金额:
$ 15.88万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 15.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 15.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 15.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)